Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) — The “Dactinomycin Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The dactinomycin market has experienced a consistent expansion, with its size expected to grow from $6.91 billion in 2025 to $7.08 billion in 2026 at a CAGR of 2.5%. This growth is attributed to early approvals of cancer drugs, widespread chemotherapy adoption in hospitals, limited alternative therapies, established clinical protocols, and robust oncology drug reimbursement systems. The market is projected to reach $7.83 billion by 2030, continuing at the same CAGR. Key factors for future growth include the rising demand for rare cancer treatments, advancements in combination therapy research, improvements in oncology diagnostics, the expansion of cancer treatment centers, and a rising global cancer incidence.
Several trends will shape the dactinomycin market, such as the stable demand for legacy chemotherapy drugs, its continued use in pediatric oncology, a focus on controlled dosage formulations, and an emphasis on drug safety monitoring. Additionally, there is growth in hospital-based oncology treatments due to the increasing cancer rates driven by aging populations, lifestyle choices, environmental factors, and genetic predispositions. Dactinomycin plays a vital role in cancer treatment by inhibiting DNA transcription, thereby disrupting cancer cell proliferation and reducing tumor growth.
The dactinomycin market’s growth is also fueled by the expansion of healthcare infrastructure, which provides the necessary support for the availability and delivery of oncology treatments. This expansion is driven by an aging global population, the rise of chronic diseases, and technological advancements. For instance, in January 2024, the American Hospital Association reported over 6,100 hospitals in the United States, demonstrating substantial healthcare capacity. Similarly, the UK’s healthcare expenditure saw significant growth, highlighting the emphasis on expanding healthcare services.
In a notable industry development, Empower Pharma, a US-based pharmaceutical company, acquired manufacturing assets from Eugia US LLC, a subsidiary of Aurobindo Pharma Ltd., for $52 million in May 2024. This strategic move aims to enhance Empower Pharma’s capabilities in sterile medication manufacturing and strengthen its position in the personalized medicine sector. Eugia US LLC is recognized for its expertise in manufacturing dactinomycin drug injections.
Leading companies in the dactinomycin market include Pfizer Inc., Teva Pharmaceutical Industries Limited, Hikma Pharmaceuticals PLC, Fresenius Kabi AG, Sandoz International GmbH, among others. In 2025, North America emerged as the largest region in the dactinomycin market, with other regions like Asia-Pacific, Western Europe, and South America also contributing significantly. The market covers sales of generic versions, formulations, and related combinations of dactinomycin. It encompasses the value of goods sold at the factory gate, including related services provided by the creators of these goods. The revenue is determined by consumption values within specified geographies, excluding resales along the supply chain.
Markets and Segments Covered:
- By Type: Injectable Solution; Lyophilized (Freeze-Dried) Powder for Injection
- By Route of Administration: Intravenous (IV); Regional or Local
- By Therapeutic Indication: Testicular Cancer; Soft Tissue and Bone Sarcomas; Pediatric Cancers
- By Distribution Channel: Hospital Pharmacies; Specialty Oncology Pharmacies
- By End User: Hospitals; Cancer Treatment Centers; Research Institutions
- Subsegments include Ready-to-Use Injectable Solution and Lyophilized Powder varieties.
Key Companies Mentioned:
- Pfizer Inc., Teva Pharmaceutical Industries Limited, Hikma Pharmaceuticals PLC, and others.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026 – 2030 |
| Estimated Market Value (USD) in 2026 | $7.08 Billion |
| Forecasted Market Value (USD) by 2030 | $7.83 Billion |
| Compound Annual Growth Rate | 2.5% |
| Regions Covered | Global |
Key Technologies & Future Trends
- Biotechnology, Genomics & Precision Medicine
- Artificial Intelligence & Autonomous Intelligence
- Digitalization, Cloud, Big Data & Cybersecurity
- Sustainability, Climate Tech & Circular Economy
- Industry 4.0 & Intelligent Manufacturing
- Stable Demand for Legacy Chemotherapy Drugs
- Continued Use in Pediatric Oncology
- Focus on Controlled Dosage Formulations
- Emphasis on Drug Safety Monitoring
- Growth in Hospital Based Oncology Treatments
Companies Featured
- Pfizer Inc.
- Teva Pharmaceutical Industries Limited
- Hikma Pharmaceuticals PLC
- Fresenius Kabi AG
- Sandoz International GmbH
- Cipla Limited
- Sun Pharmaceutical Industries Limited
- Dr. Reddy’s Laboratories Limited
- Lupin Limited
- Aurobindo Pharma Limited
- Intas Pharmaceuticals Limited
- Accord Healthcare Ltd.
- Mylan N.V.
- Zydus Lifesciences Limited
- Baxter Healthcare Corporation
- Celon Laboratories Limited
- Concord Biotech Limited
- Neon Laboratories Limited
- SGPharma Pvt. Ltd.
- Meitheal Pharmaceuticals Inc.
For more information about this report visit https://www.researchandmarkets.com/r/2ui8bb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
